Arbutus Biopharma (ABUS) Research & Development (2016 - 2025)
Arbutus Biopharma (ABUS) has disclosed Research & Development for 13 consecutive years, with $5.0 million as the latest value for Q4 2025.
- Quarterly Research & Development fell 43.18% to $5.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $25.2 million through Dec 2025, down 53.29% year-over-year, with the annual reading at $25.2 million for FY2025, 53.29% down from the prior year.
- Research & Development hit $5.0 million in Q4 2025 for Arbutus Biopharma, down from $5.8 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $22.9 million in Q4 2022 to a low of $5.0 million in Q4 2025.
- Historically, Research & Development has averaged $15.1 million across 5 years, with a median of $16.3 million in 2021.
- Biggest five-year swings in Research & Development: skyrocketed 50.97% in 2021 and later crashed 64.65% in 2025.
- Year by year, Research & Development stood at $19.2 million in 2021, then grew by 19.45% to $22.9 million in 2022, then dropped by 23.47% to $17.6 million in 2023, then plummeted by 49.84% to $8.8 million in 2024, then plummeted by 43.18% to $5.0 million in 2025.
- Business Quant data shows Research & Development for ABUS at $5.0 million in Q4 2025, $5.8 million in Q3 2025, and $5.5 million in Q2 2025.